| 2024 | | Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study | 강석윤 |
| 2024 | | Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset | 최진혁 |
| 2024 | | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | 이현우 |
| 2024 | | A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial | 이현우 |
| 2024 | | CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents | MUHAMMAD, IMRAN, 김영화, 박태준, 최용원, 최재호 |
| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
| 2024 | | Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study | 강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2024 | | Cellular senescence is associated with the spatial evolution toward a higher metastatic phenotype in colorectal cancer | 김영화, 김장희, 박순상, 박태준, 이영경, 임수빈, 최용원 |
| 2024 | | Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial | 강석윤 |
| 2024 | | Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study | 이현우 |
| 2024 | | Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study | 이현우 |
| 2024 | | Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment | 안미선, 윤준기 |
| 2024 | | Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study | 정성현, 최윤석 |
| 2024 | | Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Changes in the expression of cell interaction-related pathways during brain metastasis in lung adenocarcinoma: Gene expression and immunohistochemical analysis | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma | 고영화, 이현우, 한재호, 함석진 |
| 2024 | | Imatinib in c‑KIT‑mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18‑05 Trial) | 안미선 |
| 2023 | | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | 정성현, 최윤석 |
| 2023 | | A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13) | 안미선 |
| 2023 | | Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404) | 정성현 |
| 2023 | | Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response | 권민석 |
| 2023 | | Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation | 정성현, 최윤석 |
| 2023 | | Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma | 고영화, 박범희, 이현우, 한재호, 함석진 |
| 2023 | | Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non–Small Cell Lung Cancer | 고영화, 변혜은, 이현우, 한재호, 함석진 |
| 2023 | | The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma | 노진, 박준성, 정성현, 최윤석, 한재호 |
| 2023 | | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial | 최진혁 |
| 2023 | | Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) | 최진혁 |
| 2023 | | A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea | 최윤석 |
| 2023 | | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen | 안미선 |
| 2023 | | Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer | 안미선 |
| 2023 | | Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy | 정성현 |
| 2023 | | p15INK4B is an alternative marker of senescent tumor cells in colorectal cancer | 김영화, 김장희, 박태준, 신준상, 이영경, 임수빈, 최용원 |
| 2023 | | Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation | 박준성 |
| 2023 | | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 박준성 |
| 2023 | | Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study | 강석윤, 권민석, 김태환, 손상용, 신승수, 안미선, 이현우, 최용원, 최진혁, 한상욱, 허훈 |
| 2023 | | Radioimmunotherapy with 131I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma | 정성현 |
| 2023 | | Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study | 정성현, 최윤석 |
| 2022 | | Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy | 권민석 |
| 2022 | | 237 (PB117) - A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13) | 안미선 |
| 2022 | | The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study | 강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁 |
| 2022 | | Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01) | 최진혁 |
| 2022 | | Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin | 강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성 |
| 2022 | | Erratum: Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin | 강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성 |
| 2022 | | BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis | 노진, 정성현, 최윤석 |
| 2022 | | Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational study | 박준성 |
| 2022 | | Treatment of indolent lymphoma | 정성현 |
| 2022 | | POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation | 최윤석 |
| 2022 | | Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined with Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma | 노진, 박준성, 정성현, 최윤석 |
| 2022 | | Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 | 이현우 |
| 2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 | 강석윤 |
